Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 18/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 16/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 16/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 15/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 13/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 12/20 | 0.78 |
| ▸ | TSHR | P16473 | 10/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.78 |
| ▸ | TP53 | P04637 | 5/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.78 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4113723 | 0.87 | CYP1A2 (0.84) | CYP1A2CYP2C19CYP3A4CYP2D6HSD17B10 | |
| SCHEMBL1849614 | 0.82 | CDK9 (0.82) | CYP1A2CYP2C19CYP3A4CYP2D6HSD17B10 | |
| SCHEMBL4108273 | 0.80 | ALDH1A1 (0.68) | CYP1A2CYP2C19CYP3A4CYP2D6HSD17B10 | |
| SCHEMBL4103341 | 0.80 | CYP2D6 (0.72) | CYP1A2CYP2C19CYP3A4CYP2D6HSD17B10 | |
| SCHEMBL4111342 | 0.80 | CYP2D6 (0.82) | CYP1A2CYP2C19CYP3A4CYP2D6HSD17B10 | |
| Hydrochloric Acid SCHEMBL11786048 | 0.78 | CYP1A2 (0.83) | CYP1A2CYP2C19CYP3A4CYP2D6HSD17B10 | |
| SCHEMBL4104689 | 0.78 | CYP1A2 (0.65) | CYP1A2CYP2C19CYP3A4CYP2D6HSD17B10 | |
| SCHEMBL4103269 | 0.78 | CYP2D6 (0.75) | CYP1A2CYP2C19CYP3A4CYP2D6HSD17B10 | |
| SCHEMBL4760653 | 0.78 | CYP2D6 (0.71) | CYP1A2CYP2C19CYP3A4CYP2D6HSD17B10 | |
| SCHEMBL4109458 | 0.77 | CYP2D6 (0.73) | CYP1A2CYP2C19CYP3A4CYP2D6HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221581-A1 | Methods of treating pain | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | claimed |
| EP-1678147-A1 | PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES | GPC Biotech AG (DE) | 2006-07-12 | — | — | EP | claimed |
| WO-2005026129-A1 | PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES | GPC BIOTECH AG (DE) | 2005-03-24 | — | — | WO | claimed |
| US-8084457-B2 | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases | LEAD DISCOVERY CENTER GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20090221581-A1 | Methods of treating pain | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| EP-1901747-A2 | PYRIMIDINE-BASED CDK INHIBITORS FOR TREATING PAIN | Ingenium Pharmaceuticals AG (DE) | 2008-03-26 | — | — | EP | disclosed |
| US-20070191344-A1 | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| WO-2006125616-A2 | PYRIMIDINE-BASED CDK INHIBITORS FOR TREATING PAIN | INGENIUM PHARMACEUTICALS AG (DE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191344-A1 | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases | DAPK1, DUSP4, MARK4 | CYP1A2 4187/4885CYP2C19 3092/4885CYP3A4 2866/4885 |
| US-20090221581-A1 | Methods of treating pain | CDK5, CAMKK2, CDK3 | CYP1A2 4521/4885CYP2C19 4634/4885CYP3A4 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.